Information Provided By:
Fly News Breaks for April 20, 2015
LJPC
Apr 20, 2015 | 16:31 EDT
Oppenheimer analyst Ling Wang started shares of La Jolla Pharmaceutical with an Outperform rating and $43 price target after the close of trading today. The company has an attractive pipeline addressing multiple, large unmet medical needs, Wang told investors. Wang sees La Jolla's lead compound LJPC-501 as having a good probability of success in a pivotal phase III trial in catecholamine-resistant hypotension. Shares of La Jolla closed the trading day up $1.20 to $19.07.
News For LJPC From the Last 2 Days
There are no results for your query LJPC